Curated News
By: NewsRamp Editorial Staff
May 06, 2025
Kairos Pharma to Attend Global Conference, Showcases Breakthrough Cancer Treatment
TLDR
- Kairos Pharma (NYSE American: KAPA) will showcase at the D. Boral Capital Global Conference, enhancing investor visibility.
- Kairos Pharma focuses on oncology therapeutics, using ENV105 to target CD105 and reverse drug resistance in cancer treatment.
- Kairos Pharma's ENV105 aims to improve cancer treatment effectiveness, addressing significant unmet medical needs and enhancing patient outcomes.
- Kairos Pharma's participation in the D. Boral Capital Global Conference presents a unique opportunity for investors to engage with CEO John Yu, MD.
Impact - Why it Matters
This news matters as it highlights Kairos Pharma's innovative approach to combating drug resistance in cancer treatment. Investors can gain insights into the company's promising lead candidate, ENV105, which aims to address significant unmet medical needs in prostate and lung cancer therapy.
Summary
Kairos Pharma (NYSE American: KAPA) will be participating in the D. Boral Capital Inaugural Global Conference on May 14, 2025, allowing CEO and Chairman John Yu, MD, to engage with investors. The company focuses on oncology therapeutics, with its lead candidate ENV105 targeting CD105 to overcome drug resistance in cancer treatments. ENV105 is currently in Phase 2 and Phase 1 clinical trials for prostate and lung cancer, respectively.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Kairos Pharma to Attend Global Conference, Showcases Breakthrough Cancer Treatment
